Penpulimab
Penpulimab is a Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab.
AK105-304 phase 3: penpulimab plus gemcitabine-cisplatin improved PFS in recurrent/metastatic NPC; single-agent activity after platinum. FDA approval April 2025 for first-line combination and later-line monotherapy. Developed by Akeso (also ivonescimab, cadonilimab).
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: penpulimab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2021 | Relapsed/refractory classical Hodgkin lymphoma; later NPC, NSCLC |
| US | 2025 | Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Penpulimab" OR ABSTRACT:"Penpulimab" OR TITLE:"Penpulimab-kcqx" OR ABSTRACT:"Penpulimab-kcqx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Penpulimab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductRetifanlimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors and the tag gap-fill.
- ProductCosibelimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Immune checkpoint inhibitors and the tag gap-fill.
- TargetVISTA
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors and the tag gap-fill.
- TargetCD73 / adenosine axis
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Immune checkpoint inhibitors and the tag gap-fill.
- TermCancer during pregnancy
Shares Hodgkin lymphoma and the tag gap-fill.
- TermAdolescent and young adult (AYA) oncology
Shares Hodgkin lymphoma and the tag gap-fill.
- TargetTIM-3
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors and the tag gap-fill.
- CollectionMelanoma Research Alliance (MRA)
Shares PD-1 and the tag gap-fill.